Title: Atezolizumab for platinum-treated metastatic urothelial carcinoma
Abstract: In The Lancet, Thomas Powles and colleagues 1 Powles T Durán I van der Heijden MS et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; (published online Dec 18.)http://dx.doi.org/10.1016/S0140-6736(17)33297-X Summary Full Text Full Text PDF Scopus (886) Google Scholar report results of the IMvigor211 study—a phase 3 randomised controlled trial assessing the safety and efficacy of atezolizumab versus chemotherapy by programmed death-ligand 1 (PD-L1) expression in 931 patients with platinum-treated metastatic urothelial carcinoma. The primary endpoint, overall survival, was tested hierarchically: first in patients with PD-L1 expression on 5% or more of the immune cells (IC2/3), then in patients with PD-L1 expression on 5% and 1% or more of the immune cells (IC1/2/3), and finally in the intention-to-treat population. Statistical significance was required at each step before formal testing of the subsequent population. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialAtezolizumab was not associated with significantly longer overall survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1 (IC2/3). However, the safety profile for atezolizumab was favourable compared with chemotherapy, Exploratory analysis of the intention-to-treat population showed well-tolerated, durable responses in line with previous phase 2 data for atezolizumab in this setting. Full-Text PDF
Publication Year: 2018
Publication Date: 2018-02-01
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 10
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot